
    
      Single-centre, open-label, randomised, gender-balanced, 3-way crossover, 3-period, 3-sequence
      study in 18 healthy male and female subjects. The study consisted of 3 periods separated by a
      washout of 7 days or more between doses. Subjects received a single oral 800 mg dose of
      eslicarbazepine acetate following a standard meal in one period, and following at least 10
      hours of fasting in two periods.
    
  